台湾原发性黑色素瘤的基因改变研究
该研究对66例原发性黑色素瘤(45例肢端型、21例非肢端型)进行409个癌症相关基因的二代测序,发现肢端型中三野生型占比60%,非肢端型为24%;肢端型NRAS/KRAS突变、细胞周期异常、BIRC2/3/5拷贝数增加及受体酪氨酸激酶基因增益频率更高,且细胞周期异常与BIRC2/3/5增益与较差黑色素瘤特异性生存相关。
要点
- 肢端黑色素瘤中三野生型占60%,非肢端型占24%。
- 肢端型富集NRAS/KRAS突变、细胞周期异常及BIRC2/3/5拷贝数增加。
- 细胞周期异常和BIRC2/3/5增益与较差黑色素瘤特异性生存相关。
核心结论
- 肢端黑色素瘤与非肢端型具有不同的突变谱,肢端型中三野生型更常见,且细胞周期异常和BIRC2/3/5拷贝数增加与不良预后相关。
研究设计与样本
- 对66例原发性黑色素瘤(45例肢端型、21例非肢端型)进行409个癌症相关基因的二代测序。
主要发现
- 肢端型中三野生型肿瘤占60%(27/45),非肢端型占24%(5/21)。
- 非肢端型BRAF突变频率显著高于肢端型。
- 肢端型NRAS/KRAS突变、细胞周期异常、BIRC2、BIRC3和BIRC5拷贝数增加及受体酪氨酸激酶基因增益频率显著更高。
- 伴有细胞周期异常和受体酪氨酸激酶基因增益的黑色素瘤溃疡发生率显著更高。
- 细胞周期异常和BIRC2、BIRC3、BIRC5拷贝数增加与66例患者及45例肢端型患者的较差黑色素瘤特异性生存显著相关。
关键数值与推荐
- 多因素分析显示淋巴结转移和细胞周期异常是黑色素瘤特异性生存的独立预后因素。
临床怎么用
- 肢端黑色素瘤中富集的NRAS/KRAS突变、细胞周期异常及BIRC2/3/5拷贝数增加可能作为潜在治疗靶点。
- 细胞周期异常和BIRC2/3/5拷贝数增加可提示预后不良,需进一步探索用于未来药物开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acral melanoma (AM) is the most common histopathological subtype of malignant melanoma in Asians. However, differences in the mutational profiles underlying AM and nonacral cutaneous melanoma (NAM) in Asians are not well understood. OBJECTIVES: To augment the understanding of the prevalence, patterns and associations of various mutations between different subtypes of melanoma. METHODS: We performed comprehensive genomic profiling of 409 cancer-associated genes, using next-generation sequencing, in 66 primary melanomas comprised of 45 AMs and 21 NAMs. RESULTS: Most of the AMs (n = 27/45; 60%), but only five of 21 (24%) NAMs, were triple wild-type (triple-WT) tumours. Compared with AMs, NAMs exhibited a significantly higher frequency of BRAF mutations. The frequencies of NRAS/KRAS mutations, cell-cycle aberrations, copy number gains in BIRC2, BIRC3 and BIRC5, and gains of receptor tyrosine kinase genes were significantly higher in AMs. Ulceration was found at significantly higher rates in the AMs and NAMs with cell-cycle aberrations and gains of receptor tyrosine kinase genes. Notably, cell-cycle aberrations and copy number gains in BIRC2, BIRC3 and BIRC5 were significantly associated with poor melanoma-specific survival in the 66 patients with melanoma and especially in the 45 patients with AM. Multivariate analysis showed that lymph node metastasis and cell-cycle aberrations were independent prognostic factors of melanoma-specific survival. CONCLUSIONS: This study strengthens our understanding of the patterns and clinical associations of oncogenic mutations in AMs and NAMs in Asians. What's already known about this topic? Mutation frequencies of driver genes vary between melanoma subtypes. Acral melanoma is the most common subtype of melanoma in Asians. KIT mutations and copy number variations occur more frequently in the acral subtype of melanoma than in the nonacral subtype What does this study add? NRAS/KRAS mutations, cell-cycle aberrations, copy number gains in BIRC2, BIRC3 and BIRC5, and amplifications of receptor tyrosine kinase genes were significantly enriched in acral melanoma and could be potential targets for treatment. Melanomas with cell-cycle aberrations and gains in receptor tyrosine kinase genes were significantly more likely to contain ulceration. What is the translational message? Cell-cycle aberrations and copy number gains in BIRC2, BIRC3 and BIRC5 were significantly associated with poor melanoma-specific survival. These observations should be explored further for future drug development.
引用
- Sheen YS, Tan KT, Tse KP, et al. Genetic alterations in primary melanoma in Taiwan. Br J Dermatol. 2019. PMID: 31408190. doi:10.1111/bjd.18425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。